TP53 and acute myeloid leukemia: For acute myeloid leukemia (AML), the patient’s genetic profile should be obtained first, even if this means delaying the start of the treatment, as recommendations are different if the disease has unfavorable markers (e.g., mutations in the tumor suppressor TP53), is secondary to a previous treatment, and if the patient is “fit” or “unfit” [65].